ArticleChemistry, an Asian journal2026
Structural Optimization of Dithiaarsanes-Enhanced Cytotoxicity to Leukemia Cells With Improved Thioredoxin Reductase Inhibition.
Article in Chemistry, an Asian journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Insights into the activation patterns of 1,2-dithiolane unit in biofunctional molecules.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Herein, we report the rational design and optimization of dithiaarsane-based organoarsenicals that target thioredoxin reductase (TrxR), a selenoenzyme essential for maintaining cellular redox balance and often upregulated in various cancers. Guided by structure-activity relationship (SAR) analysis, refinement of the arsenic-sulfur heterocyclic scaffold afforded compound 37, which exhibits potent cytotoxicity against HL-60 leukemia cells. Mechanistic studies revealed that compound 37 efficiently inhibits TrxR activity, increases intracellular reactive oxygen species, and triggers apoptosis. Collectively, these results, together with the chemically versatile dithiaarsane scaffold established herein, provide a solid foundation for the development of next-generation TrxR-targeted therapeutics and redox-responsive functional molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.